Worldwide HealthcareWWH:LSE

1,752
3.00 / 0.17%
92.08k
7.79 %
0.724
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of May 26 2016 17:36 BST.

Total returns on £1000

Fund / BenchmarkChange
PriceWorldwide Healthcare (Ordinary Share)-8.82 %
Worldwide Healthcare (Ordinary Share)-8.43 %
Morningstar's BenchmarkFTSE World-0.70 %
As of May 16 2016.

Worldwide Healthcare summary

Shares outstanding47.31m
Market cap828.40m GBP
Total assets995.70m GBP
Total expense ratio0.96%
Day high1,755
Day low1,740
Previous close1,749
Average volume95.83k
YTD Change-9.64 %
Beta0.7240%
Diluted NAV (est)1,891.47
Diluted NAV (last pub)1,885.4
Premium/Discount-7.37 %
Gearing+112.00 %
52-week range
Today
1,541
Feb 09 2016
2,108.5
Jul 21 2015

As of last trade, WWH:LSE traded at 1,752, 13.69% above the 52 week low of 1,541 set on Feb 09, 2016.

Data delayed at least 15 minutes, as of May 26 2016 17:36 BST.

Profile

Management group(s)Frostrow Capital LLP / OrbiMed Capital LLC
AIC sectorSector Specialist: Biotechnology/Life Sciences
ISINGB0003385308
Launch date28 Apr 1995
Share typeOrdinary Share
StructureConventional
Base currencyGBP

Objective

To invest worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.

Management & contract fees

The Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The performance fee amounts to 16.5% of any out-performance of the NAV over the benchmark index.

Dividend

Div yield0.82587
Div ex-date26 Nov 2015
Div pay-date08 Jan 2016

Managed by

Sven Borho Start : 01 Feb 2013
Samuel. D Isaly Start : 28 Apr 1995
Trevor M. Polischuk Start : 31 Mar 2015
Data delayed at least 15 minutes, as of May 26 2016 17:36 BST.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.